These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12431044)

  • 1. Single dose of ketotifen fumarate .025% vs 2 weeks of cromolyn sodium 4% for allergic conjunctivitis.
    Greiner JV; Michaelson C; McWhirter CL; Shams NB
    Adv Ther; 2002; 19(4):185-93. PubMed ID: 12431044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A placebo-controlled comparison of ketotifen fumarate and nedocromil sodium ophthalmic solutions for the prevention of ocular itching with the conjunctival allergen challenge model.
    Greiner JV; Minno G
    Clin Ther; 2003 Jul; 25(7):1988-2005. PubMed ID: 12946546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The anti-allergic effects of a cromolyn sodium-chlorpheniramine combination compared to ketotifen in the conjunctival allergen challenge model.
    Leonardi A; Busca F; Tavolato M; Secchi AG
    Eur J Ophthalmol; 2003 Mar; 13(2):128-33. PubMed ID: 12696630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial.
    Crampton HJ
    Clin Ther; 2003 Jul; 25(7):1975-87. PubMed ID: 12946545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioequivalence of two formulations of ketotifen fumarate ophthalmic solution: a single-center, randomized, double-masked conjunctival allergen challenge investigation in allergic conjunctivitis.
    Torkildsen GL; Abelson MB; Gomes PJ
    Clin Ther; 2008 Jul; 30(7):1272-82. PubMed ID: 18691986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of ketotifen fumarate 0.025% in the conjunctival antigen challenge model of ocular allergic conjunctivitis.
    Greiner JV; Mundorf T; Dubiner H; Lonsdale J; Casey R; Parver L; Kapik BM; Shams NB; Abelson MB
    Am J Ophthalmol; 2003 Dec; 136(6):1097-105. PubMed ID: 14644221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of ketotifen fumarate 0.025% ophthalmic solution compared with placebo in the conjunctival allergen challenge model.
    Abelson MB; Chapin MJ; Kapik BM; Shams NB
    Arch Ophthalmol; 2003 May; 121(5):626-30. PubMed ID: 12742839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of single- and multiple-dose ketotifen fumarate 0.025% ophthalmic solution in a pediatric population.
    Abelson MB; Ferzola NJ; McWhirter CL; Crampton HJ
    Pediatr Allergy Immunol; 2004 Dec; 15(6):551-7. PubMed ID: 15610370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the relative clinical efficacy of a single dose of ketotifen fumarate 0.025% ophthalmic solution versus placebo in inhibiting the signs and symptoms of allergic rhinoconjunctivitis as induced by the conjunctival allergen challenge model.
    Crampton HJ
    Clin Ther; 2002 Nov; 24(11):1800-8. PubMed ID: 12501875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, double-masked, placebo-controlled comparison of the efficacy of emedastine difumarate 0.05% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the human conjunctival allergen challenge model.
    D'Arienzo PA; Leonardi A; Bensch G
    Clin Ther; 2002 Mar; 24(3):409-16. PubMed ID: 11952024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the onset and duration of effect of azelastine eye drops (0.05%) versus placebo in patients with allergic conjunctivitis using an allergen challenge model.
    Friedlaender MH; Harris J; LaVallee N; Russell H; Shilstone J
    Ophthalmology; 2000 Dec; 107(12):2152-7. PubMed ID: 11097587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial.
    Borazan M; Karalezli A; Akova YA; Akman A; Kiyici H; Erbek SS
    Acta Ophthalmol; 2009 Aug; 87(5):549-54. PubMed ID: 18631332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge.
    Mah FS; Rosenwasser LJ; Townsend WD; Greiner JV; Bensch G
    Curr Med Res Opin; 2007 Jun; 23(6):1445-52. PubMed ID: 17559743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model.
    Lanier BQ; Finegold I; D'Arienzo P; Granet D; Epstein AB; Ledgerwood GL
    Curr Med Res Opin; 2004 Aug; 20(8):1227-33. PubMed ID: 15324525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ocular tolerability and safety of ketotifen fumarate ophthalmic solution.
    Abelson MB; Chapin MJ; Kapik BM; Shams NB
    Adv Ther; 2002; 19(4):161-9. PubMed ID: 12431041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model.
    Butrus S; Greiner JV; Discepola M; Finegold I
    Clin Ther; 2000 Dec; 22(12):1462-72. PubMed ID: 11192137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model.
    Berdy GJ; Spangler DL; Bensch G; Berdy SS; Brusatti RC
    Clin Ther; 2000 Jul; 22(7):826-33. PubMed ID: 10945509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate.
    Abelson M; Howes J; George M
    J Ocul Pharmacol Ther; 1998 Dec; 14(6):533-42. PubMed ID: 9867336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of 0.05% levocabastine versus 4% sodium cromolyn in the allergen challenge model.
    Abelson MB; George MA; Smith LM
    Ophthalmology; 1995 Feb; 102(2):310-6. PubMed ID: 7862419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis.
    Katelaris CH; Ciprandi G; Missotten L; Turner FD; Bertin D; Berdeaux G;
    Clin Ther; 2002 Oct; 24(10):1561-75. PubMed ID: 12462286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.